ty -jour t1-慢性阻塞性肺疾病中吸入的皮质类固醇和存活：剂量重要吗？JF-欧洲呼吸杂志JO -EUR RESSIR J SP -260 LP -266 DO -10.1183/09031936.03.00040803 VL -21 IS -2 AU -SIN，D.D.Au -Man，S.F.P。Y1-2003/02/01 UR -http：//www.qdcxjkg.com/content/21/2/2/260.abstract N2-最近的数据表明，吸入的皮质类固醇减少了慢性阻塞性肺疾病（COPD）中临床病情的临床病情数量。是否存在剂量/反应关系仍然未知。进行了本研究以评估不同剂量的吸入皮质类固醇对COPD死亡率的长期影响。医院出院数据用于识别加拿大艾伯塔省COPD最近住院的所有年龄≥65岁的所有患者（n = 6,740）。住院后，比较了不同剂量类别的皮质类固醇（无和低剂量和高剂量）的全因死亡率的相对风险（RR）。排出后吸入的皮质类固醇治疗与全因死亡率的风险相对降低25％（RR 0.75，95％的置信区间（CI）0.68-0.82）。中剂量或高剂量治疗的患者的死亡率比低剂量的患者较低（低剂量的RR 0.77，95％CI 0.69-0.86；中剂量0.48，95％CI 0.37-0.63，中等剂量； RR 0.55，RR 0.55，RR 0.55，RR 0.55，RR 0.55，RR 0.55，RR 0.37-0.63 95% CI 0.44–0.69 for high dose). Use of inhaled corticosteroids following hospital discharge for chronic obstructive pulmonary disease was associated with a significant reduction in the overall mortality rate. Low- was inferior to medium- or high-dose therapy in protecting against mortality in chronic obstructive pulmonary disease. D.D. Sin is supported by a New Investigator Award from the Canadian Institutes of Health Research, Ottawa, Canada, and a Population Health Investigator Award from the Alberta Heritage Foundation for Medical Research, Edmonton, Canada. ER -